Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00563147
Other study ID # AV-951-07-102
Secondary ID
Status Completed
Phase Phase 1
First received November 21, 2007
Last updated September 30, 2011
Start date November 2007
Est. completion date February 2011

Study information

Verified date September 2011
Source AVEO Pharmaceuticals, Inc.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to test the safety and tolerability of tivozanib (AV-951) and Torisel™ given in combination for renal cell cancer. The study will also assess the effects of the combination of tivozanib (AV-951) and Torisel™ on the tumor. Tivozanib (AV-951) is a VEGF-receptor tyrosine kinase inhibitor, and may stop the growth of tumor cells by blocking blood flow to the tumor. Temsirolimus is an mTOR inhibitor which is approved for the treatment of advanced renal cell carcinoma.


Description:

This is a Phase 1b, open-label, dose-finding study of tivozanib (AV-951) in combination with temsirolimus to include approximately 36 subjects with metastatic renal cell carcinoma (mRCC). This study is designed to evaluate the safety, tolerability, dose-limiting toxicities (DLT), maximum tolerated dose (MTD), pharmacokinetic, pharmacogenomic, and antineoplastic activity of tivozanib (AV-951) when administered in combination with temsirolimus. Tivozanib (AV-951) will be administered once daily for 3 weeks beginning on Day 1 of Cycle 1, followed by 1 week off (1 cycle = 4 weeks). Temsirolimus will be administered intravenously once weekly starting on Day 8 of Cycle 1.


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date February 2011
Est. primary completion date November 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- = 18-year-old males or females

- Histologically confirmed renal cell carcinoma with a clear cell component

- Documented progressive disease

- Measurable disease by RECIST criteria

- No more than 1 prior VEGF receptor targeted therapy; no prior treatment with temsirolimus or other drugs targeting the mTOR pathway

- Karnofsky performance status > 70%; life expectancy = 3 months

- Ability to give written informed consent

Exclusion Criteria:

- Known hypersensitivity to temsirolimus or its metabolites (including sirolimus), polysorbate 80, or to any other component of the temsirolimus formulation

- Primary CNS malignancies; active CNS metastases

- Hematologic malignancies (including leukemia in any form, lymphoma, and multiple myeloma)

- Any of the following hematologic abnormalities:

- Hemoglobin < 9.0 g/dL

- ANC < 1500 per mm3

- Platelet count < 100,000 per mm3

- Any of the following serum chemistry abnormalities:

- Fasting serum cholesterol > 350 mg/dL

- Fasting triglycerides > 400 mg/dL

- Total bilirubin > 1.5 × ULN

- AST or ALT > 2.5 × ULN (or > 5 x ULN in subjects with liver metastasis)

- Serum albumin < 3.0 g/dL

- Creatine > 1.5 × ULN (or calculated CLCR <50 mL/min/1.73 m2)

- Proteinuria > 2.5 g/24 hours or 3+ with urine dipstick

- Significant cardiovascular disease, including:

- Active clinically symptomatic left ventricular failure

- Active hypertension (diastolic blood pressure > 100 mmHg). Subjects with a history of hypertension must have been on stable doses of anti-hypertensive drugs for = 4 weeks

- Uncontrolled hypertension: Blood pressure >140/90 mmHg on 2 or more antihypertensive medications

- Myocardial infarction within 3 months prior to administration of first dose of study drug

- Subjects with delayed healing of wounds, ulcers, and/or bone fractures

- Pulmonary hypertension or pneumonitis

- Serious/active infection; infection requiring parenteral antibiotics

- Inadequate recovery from any prior surgical procedure; major surgical procedure within 6 weeks prior to study entry

- Uncontrolled psychiatric disorder, altered mental status precluding informed consent or necessary testing

- Inability to comply with protocol requirements

- Ongoing hemoptysis or history of clinically significant bleeding

- Cerebrovascular accident within 12 months of study entry, or peripheral vascular disease with claudication on walking less than 1 block

- Deep venous thrombosis or pulmonary embolus within 6 months of study entry and/or ongoing need for full-dose oral or parenteral anticoagulation

- Subjects with a "currently active" second primary malignancy other than non-melanoma skin cancers. Subjects are not considered to have a "currently active" malignancy if they have completed anti-cancer therapy and are considered by their physician to be < 30% risk of relapse.

- Pregnant or lactating women

- Known concomitant genetic or acquired immune suppression disease such as HIV

Prohibited medications:

- VEGF receptor (VEGFR) targeted therapy within 4 weeks prior to and during study

- Other signal transduction inhibitors, monoclonal antibodies, etc., within 4 weeks prior to and during study

- Immunotherapy or biological response modifiers within 4 weeks prior to and during study

- Systemic hormonal therapy within 4 weeks prior to and during study, with the exception of:

- Hormonal therapy for appetite stimulation or contraception

- Nasal, ophthalmic, and topical glucocorticoid preparations

- Oral replacement therapy for adrenal insufficiency

- Low-dose maintenance steroid therapy for other conditions

- Herbal preparations/supplements (except for a daily multivitamin/mineral supplement not containing herbal components) within 2 weeks prior to or during study

- Any experimental therapy 4 weeks prior to and during study

- Radiotherapy:

- At least 2 weeks since prior local radiation therapy (ie, involving <25% of bone marrow) at the time of study entry

- At least 4 weeks since prior radiation therapy involving = 25% of bone marrow

- Treatment with CYP3A4 inducers or inhibitors during the study

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
tivozanib (AV-951) plus temsirolimus
ascending doses of tivozanib (AV-951) capsules administered orally for 21 days with discontinuation for 7 days; ascending doses of temsirolimus administered intravenously every 7 days

Locations

Country Name City State
United States The Methodist Hospital Research Institute Houston Texas
United States UCLA Jonsson Comprehensive Cancer Center Los Angeles California
United States Nebraska Methodist Hospital Omaha Nebraska
United States Stanford University Stanford California
United States H. Lee Moffitt Cancer Center Tampa Florida

Sponsors (1)

Lead Sponsor Collaborator
AVEO Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To determine the safety and tolerability of tivozanib (AV-951) when given in combination with temsirolimus 4 weeks (1 cycle) Yes
Secondary To characterize the pharmacokinetic profile of tivozanib (AV-951) and temsirolimus when administered in combination 8 weeks (2 cycles) No
Secondary To evaluate the antineoplastic activity of tivozanib (AV-951) and temsirolimus when administered in combination 8 weeks (2 cycles) No
Secondary To evaluate the effect of tivozanib (AV-951) and temsirolimus on global and targeted gene expression patterns 8 weeks (2 cycles) No
Secondary To determine the maximum tolerated dose (MTD) of tivozanib (AV-951) when administered in combination with temsirolimus 4 weeks (1 cycle) Yes
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04987203 - Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Phase 3
Recruiting NCT06391879 - Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Terminated NCT03655613 - APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC Phase 1/Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Withdrawn NCT05418387 - A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona N/A
Recruiting NCT04623502 - An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy N/A
Completed NCT02853344 - Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427) Phase 2
Terminated NCT04088500 - A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma Phase 2
Completed NCT05070637 - Circulating Tumor Cell Reducing No-touch Nephrectomy N/A
Active, not recruiting NCT03634540 - A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) Phase 2
Not yet recruiting NCT06049030 - A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma Phase 1
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT01358721 - Phase I Biomarker Study (BMS-936558) Phase 1
Active, not recruiting NCT04503148 - Anesthesia and Cancer Study: Renal Cell Carcinoma N/A
Completed NCT02386826 - INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme Phase 1
Not yet recruiting NCT05808608 - A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma Phase 1/Phase 2
Withdrawn NCT03323710 - Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma Phase 2
Completed NCT03052504 - Prospective Versus Retrospective Complications in Radical Cystectomy and Nephrectomy